prikaz prve stranice dokumenta Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
  Download
PDF 1.17 MB
Scientific paper - Original scientific paper
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Blood Cancer Journal, 12 (2022), 4; 71. https://doi.org/10.1038/s41408-022-00668-8
Pratz, Keith W.; Panayiotidis, Panayiotis; Recher, Christian; Wei, Xudong; Jonas, Brian A.; Montesinos, Pau; Ivanov, Vladimir; Schuh, Andre C.; DiNardo, Courtney D.; Novak, Jan; Pejša, Vlatko; Stevens, Don; Yeh, Su-Peng; Kim, Inho; Turgut, Mehmet; Fracchiolla, Nicola; Yamamoto, Kazuhito; Ofran, Yishai; Wei, Andrew H.; Bui, Cat N.; Benjamin, Katy; Kamalakar, Rajesh; Potluri, Jalaja; Mendes, Wellington; Devine, Jacob; Fiedler, Walter More authors...

Citations:
,
Cite this document

Pratz, K. W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B. A., Montesinos, P. ... Fiedler, W. (2022). Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 12. (4). doi: 10.1038/s41408-022-00668-8

Pratz, Keith W., et al. "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia." Blood Cancer Journal, vol. 12, no. 4, 2022. https://doi.org/10.1038/s41408-022-00668-8

Pratz, Keith W., Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, et al. "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia." Blood Cancer Journal 12, no. 4 (2022). https://doi.org/10.1038/s41408-022-00668-8

Pratz, K. W., et al. (2022) 'Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia', Blood Cancer Journal, 12(4). doi: 10.1038/s41408-022-00668-8

Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, and sur.. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal [Internet]. 2022 April 20 [cited 2025 April 03];12(4). doi: 10.1038/s41408-022-00668-8

K. W. Pratz, et al., "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia", Blood Cancer Journal, vol. 12, no. 4, April 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:795165. [Accessed: 03 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
AuthorKeith W. Pratz
AuthorPanayiotis Panayiotidis
AuthorChristian Recher
AuthorXudong Wei
AuthorBrian A. Jonas
AuthorPau Montesinos
AuthorVladimir Ivanov
AuthorAndre C. Schuh
AuthorCourtney D. DiNardo
AuthorJan Novak
AuthorVlatko Pejša
AuthorDon Stevens
AuthorSu-Peng Yeh
AuthorInho Kim
AuthorMehmet Turgut
AuthorNicola Fracchiolla
AuthorKazuhito Yamamoto
AuthorYishai Ofran
AuthorAndrew H. Wei
AuthorCat N. Bui
AuthorKaty Benjamin
AuthorRajesh Kamalakar
AuthorJalaja Potluri
AuthorWellington Mendes
AuthorJacob Devine
AuthorWalter Fiedler
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration... More (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBlood Cancer Journal
Numberingvol. 12, no. 4, 71
e-ISSN2044-5385
DOIhttps://doi.org/10.1038/s41408-022-00668-8
URN:NBNurn:nbn:hr:105:795165
Publication2022-04-20
Document URLhttps://www.nature.com/articles/s41408-022-00668-8
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-12-15 10:58:20
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.